Uncategorized
Aerie reports $18 million GAAP net loss
Aerie Pharmaceuticals reported a GAAP net loss of $18 million, or $0.69 per share, in the third quarter compared with a GAAP net loss of $13.1 million, or $0.54 per share, in the same quarter of 2014, according to a press release. Operating expenses were reported at $17.4 million compared with $13.2 million in the same quarter of 2014. The increase was attributed to increased activities related to phase 3 programs for Rhopressa and Roclatan, as well as associated growth in activities.